Clinical trial registry record

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 19, 2012.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00463320
Last registry update
March 19, 2012
Status
Completed
Phase
Phase 1
Sponsor
GlaxoSmithKline
Enrollment
29
Countries
United States
Match confidence
70%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · PARALLEL · DIAGNOSTIC · SINGLE
Evidence population
Human clinical study registration
Participants
29
Population
ALL · 30 Years to 55 Years
Duration
2007-03-01 to 2007-08-01
Intervention
Pazopanib eye drops and Allergen Refresh Plus eye drops
Comparator
Not reported
Outcomes measured
Ocular safety by observation and eye exams. — at baseline, each dosing day and follow-up; General safety by PE, VS, cardiac monitoring, clinical laboratory tests and adverse events reporting . — day-1,5,10,14; Pazopanib exposure by AUC and Cmax . — day 1,14; Pazopanib exposure measured by secondary pharmacokinetic parameters at day 1 and 14.; Safety endpoints include complete ophthalmic examination, vital signs (heart rate and blood pressure), cardiac monitori…; Change in visual acuity (number of letters read on standardized ETDRS charts).; Change in retinal morphology (i.e. CNV, intraretinal cysts, intraretinal fluid, subretinal fluid, and retinal pigment e…; Change in neovascular size, lesion size and characteristics (fibrosis, atrophy, blood) as measured by fluorescein angio…; Cmax, tmax, and AUC(0-24) of plasma pazopanib, if data are sufficient.
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 70% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 70%Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON